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s u m m a r y 
Hepatitis C virus (HCV) is the primary etiologic agent of liver cirrhosis or hepatocellular carcinoma. HCV 
elevated infection rates are mostly due to the lack of an accurate and accessible screening and diagno- 
sis, especially in low- and middle-income countries. Conventional HCV diagnostic algorithm consists of 
a serological test followed by a nucleic acid test. This sequence of tests is time consuming and not af- 
fordable for low-resource settings. Nanotechnology have introduced new promising tests for the diagnose 
of infectious diseases. Based on the employment of nanoparticles and other nanomaterials which lead to 
highly sensitive and specific nanoscale tests, most of them target pathogen genome. Implementation of 
nanoscale tests, which are affordable, portable and easy to use by non-specialized personal, would im- 
prove HCV diagnosis algorithm. In this review, we have summed up the current emerging nanotechnology 
tools, which will improve actual screening and treatment programs, and help to reach HCV elimination 
proposal. 
© 2019 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 




































t  Introduction 
Hepatitis C virus (HCV) is the primary etiologic agent of liver
cirrhosis or hepatocellular carcinoma. Up to eight major genotypes
(1–8) and 86 subtypes [1 , 2] have been described so far. Among
them, the type 1 the most common genotype worldwide, followed
by type 3 [3] . Besides, HCV genotypes are differently distributed
worldwide, with China and South-East Asia showing the most
diverse genotypes [4] . 
Despite the introduction of new Direct-Acting Antiviral Agents
(DAAs) hepatitis C virus (HCV) infection remains as a global health
problem. It represents one of the principal cause of deaths related
to liver cirrhosis and hepatocellular carcinoma [5] and the World
Health Organization (WHO) has recently estimated around 71
million viraemic chronic infections and 40 0.0 0 0 related deaths,
and a prevalence of 1 ·1% in 2017 [6] . Number of deaths caused by
Hepatitis C is still increasing, despite the fact that highly effective
medicines already exist to cure chronic hepatitis C. WHO objective
to eradicate HCV for 2030 could be reached [7] but for this purpose
it is required more efficient screening and treatment programs. ∗ Corresponding author. 
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( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) DAAs can satisfactory deal with more than 95% of HCV-infected
eople, reducing the risk of death from liver cancer and cirrhosis
s a result. However, since these drugs are too expensive there is
 socioeconomical barrier for large scale treatment in particular
n low- and middle-income countries (LMICs). Thus, less than
% of patients infected with HCV worldwide can access to DAAs
reatment [6] . On the other hand, an efficient and cheap diagnostic
olicy is also instrumental to achieve HCV eradication. Under-
iagnosis of HCV remains a serious challenge, so fast and reliable
iagnosis tests are the main objective to improve treatment ac-
ess. Current diagnostic methods for HCV detection are based on
erological and molecular tests. However, they are time-consuming
nd expensive; they require modern laboratory infrastructure and
xpert personnel that avoid their implementation in difficult-to-
each population with no access to hospitals and in LMICs. Of note,
enotyping of HCV may no longer be necessary shortly as future
an-genotypic HCV DAAs will simplify the treatment strategy [4] . 
It is critical to develop reliable alternative diagnostic tools for
CV infection in order to overcome the diagnostic barriers and
herefore to reach those undiagnosed HCV-infected people. New
iagnostic devices should be fast, affordable, time-saving, and
apable to reduce the window period for HCV detection, with high
ates of efficacy and sensitivity as well. ion Association. This is an open access article under the CC BY-NC-ND license. 































































































































a  The aim of this review is to provide an overview of the new
romising alternative tools related to the screening and diagnosis
f HCV infection, based on the emerging area of nanotechnology. 
onventional systems for HCV diagnosis 
Conventional diagnostic systems for HCV infection involved
erological biomarkers and molecular tests. Serological biomarkers
ay detect anti-HCV antibodies or HCV antigens, while molecular
ests detect HCV RNA. Currently the use of serological assays to
etect anti-HCV antibodies is the first step within HCV testing
lgorithm, because they are easy to handle and more afford-
ble than molecular assays. However, the detection of anti-HCV
ntibodies cannot confirm active HCV infection, since HCV spe-
ific immunoglobulins remain in the organism longtime after viral
learance. Thus, a molecular test for HCV RNA detection is required
s a final step [4] . Another drawback of serological tests is that
hey can not detect HCV infection in early stages, since detection
f antibodies requires at least two weeks after primo-infection [8] .
The gold standard serological test to detect anti-HCV antibodies
re the third generation of enzyme immunoass ays (EIA) as ORTHO
CV Version 3.0 ELISA Test System (Ortho Diagnostic Systems,
SA) and Murex anti-HCV 4.0 (Murex Diagnostics, UK) multiplex
hat detect anti-HCV antibodies employing different core, NS3,
S4, and NS5 recombinant antigens. Their high specificity and
ensitivity are around 99 ·4–100% in both EIA commercial systems
9 , 10] have boosted their use in industrialized countries. 
Variants of the EIA include chemiluminescent immunoassays
CLIA), as it is the case of Foresight HCV EIA test (ACONLabs,
S) (99 ·8% specificity and > 99 ·9% sensitivity) [11] , enzymatic
LIAs as luminol-H 2 O 2 -horseradish peroxidase (HRP) [12] , and
hemiluminescent microparticle immunoassays (CMIA), as ARCHI- 
ECT (Abbott Diagnostics, USA) which is also able to detect viral
nfections by HBV and HIV-1. 
Fluorescence immunoassays , like VIDAS test (BioMerieux, Marcy
’Etoile, France), also detects anti-HCV IgGs. Of note, this brand is
ore sensitive (99 ·8%) and specific (99 ·61%) for low titer samples
han Ortho HCV [9 , 13] . As ARCHITECT CMIA, VIDAS test was first
eveloped for detection of similar viruses such as HAV, HBV, and
IV, and since 2017 it also detects the 6 different HCV genotypes
13 , 14] . Fluorescence detection methodology has also been im-
lemented to develop protein chip microarrays, which are also
idely used in diagnostic. Zhang et al. (2005) developed a protein
hip for anti-HCV antibody detection based on ELISA methodology,
hich improves ELISA specificity and sensitivity: 100% coincidence
ate between ELISA and protein chip for negative results, and
9 ·5% or 97 ·4%, in regard to the recombinant antigen used, for
ositive results (ELISA shows a higher number of false positive
esults) [15] , which reinforce that new methodologies are better
han conventional ELISA. 
Confirmatory serological tests are hardly used nowadays.
rtho-HCV RIBA-2 (Ortho Diagnostic Systems, Raritan, N.J., USA),
as one of the most confirmatory tests used. However, false
egative or negative results have been reported using this test
16] . Matrix Immunodot HCV Assay (Abbott Laboratories, USA) and
ew generation assays that include recombinant antigens, such as
urex anti-HCV 4.0 (Murex Diagnostics, UK), are more specific,
nd therefore they have had a broader use [17] . 
However, the determination of HCV viremia must be finally
onfirmed through molecular methods in order to identify an
ctive HCV infection, as recommended by WHO [4] . This detection
f HCV RNA is the only way to determine an active HCV infection,
ince anti-HCV antibodies remain in the organism long-time after
irus clearance [4 , 8 , 18] . Different quantitative molecular methods
o determine viremia have been developed so far. To highlight, the
se of real time RT-qPCR technology like COBAS Amplicor HCVest (Roche, US) [19] , and Abbott RealTime HCV assay (Abbott
ssay, Abbott Labs Illinois, US). Despite the robustness of this
echnology, one of the most important drawbacks of molecular
ethods is the complexity of the laboratory equipment required,
or instance the variety of lasers for detection of fluorescence dyes
n RTqPCR [20 , 21] . 
It is noteworthy that WHO recommend testing for bloodborne
iruses like HIV, HBV, and infections such as TB [4] among HCV
isk populations. Thus, multiplex assays are required in viral
etection in these groups. Yang et al. (2014) proposed to develop
 multiplex assay by coupling new specific probes against HIV or
BV to their bead array test [22] . Conventional molecular methods
an detect HBV, HCV, HIV-1, and HIV-2 in a single test, such as
PCR COBAS TaqScreen MPX test v2.0 (Roche Molecular Systems
nc., Pleasanton CA, US) . 
Alternative molecular methods include the Transcription- 
ediated Amplification (TMA), which employs acridinium labelled
robes and magnetic microparticles to form detectable complexes
23] . TMA has a better sensitivity than PCR assay amplification
 < 9 ·6 IU/mL) as determined by Morishima et al. (2006) for the
ommercial test VERSANT HCV RNA Qualitative Assay (Siemens
ealthcare Diagnostics, Eschborn, Germany) versus conventional
CR AMPLICOR HCV Test, v. 2.0 assay (Roche Diagnostics, Ger-
any) [24] . VERSANT HCV bDNA 3.0 Assay is a quantitative
ersion developed in order to determine viral load, and has a very
imilar capability to quantify RNA compared with COBAS AM-
LICOR HCV Monitor assay version 2.0 [25] . Regarding multiplex
nalysis, Procleix Ultrio Elite Assay (Grifols Diagnostic Solutions,
nc., USA) is a qualitative test based on TMA technology developed
o detect HIV-1, HIV-2, HCV (genotypes 1–6), and HBV (genotypes
-H) in serum or plasma samples at the same time [26] . However
MA is a technique that still requires exclusive and expensive
nstrumentation, not affordable for developing countries. 
Current multiplex assays are expensive and time consuming,
o standardization of them still remains a challenge. In order to
educe time and cost of multiplex assays, Sing et al. (2017) devel-
ped a single-step multiplex RT-qPCR to discriminate among dif-
erent HCV genotypes. Currently, single-step multiplex assay re-
uires two separate assays to detect the 6 genotypes: one reaction
or genotypes 2, 3, 4, and 5, and another reaction for genotypes 1
nd 6. Their study showed that single-step multiplex RT-qPCR has
00% specificity and 94 ·89% sensitivity. Cost-effective and time-
aving genotyping tests are needed until pangenotypic DAAs be-
ome more established [27] highlighting the value of this new test.
lternatives to molecular tests 
Most of LMIC use anti-HCV antibody screening tests and only
 reduced percentage of these countries have access to HCV RNA
ests (between 5 and 30%, as determined by Reipold E.I. et al.,
017) [28] . The requirements of molecular tests for high specific
nd expensive analytical equipment make difficult their imple-
entation in LMIC. However, serological tests cannot detect HCV
nfection at early stages or in immunosuppressed patients [29 , 30] .
ecause of that, detection of HCV core antigen is becoming an al-
ernative option in resource-limited settings: as an indirect marker
f HCV RNA, it can correlate with viremia values and determine
n active infection. HCV core antigen could be detected in those
latforms that detect anti-HCV antibodies, making easier their
mplementation in LMIC. HCV antigen tests are more expensive
han antibody tests, but they reduce the costs associated with
nstrumentation compared to molecular methods [31 , 32] . 
HCV core antigen test could be used as an alternative confirma-
ory assay instead of HCV RNA tests. However, since its sensitivity
s lower than molecular tests, only a positive result of HCV core
ntigen makes the HCV RNA test unnecessary [32] . Moreover, core






















































































































s  antigen disappears later than RNA so it can be used to detect later
phases of HCV infection when HCV RNA is undetectable [31] . 
Examples of HCV core antigen tests include HRP-based CLIA
systems as described by Lui et al. (2015) with high specificity
(96 ·7%) and sensibility at low concentrations (0 ·6 pg/mL) [12] .
CMIA test (Abbott HCV cAg assay, Abbott Diagnostics, USA) can be
also used to detect HCV Core antigen. Its sensitivity is about 93%
and shows higher specificity (98 ·8% versus 96 ·7%) with the system
described by Lui et al. (2015). Nevertheless, it is not yet systemat-
ically used in these LMIC countries because of its costs [28] . 
In summary, LMICs only have routinely access to serological
tests. Moreover, just a reduced population group (between 5 and
30%) [28] have access to HCV RNA tests, which ends up in an
important percentage of undiagnosed population, due to immuno-
suppression or screening in pre-seroconversion stages. In addition,
there are people who are diagnosed as HCV positive and thus they
start receiving treatment when they present anti-HCV antibodies,
but could have spontaneously cleared HCV infection [28 , 33] . Thus,
implementing HCV molecular or antigen tests in resource-limited
countries will reduce the unnecessary medical treatment. For this
purpose, affordable nucleic acid amplification tests (NAAT) or HCV
core antigen point-of-care (POC) tests have to be developed. 
Rapid diagnostic tests 
Rapid diagnostic tests (RDTs) are designed for its use at the
POC, and can be adapted in low-resource settings. Under-diagnosis
of HCV remains a serious challenge in order to achieve HCV elim-
ination. Development of new diagnostic tools that do not require
laboratory infrastructure and expertise in their operation, reduce
the economic cost and time of diagnosis, are essential particularly
in difficult-to-reach population and in LMICs. 
Serological rapid POC tests already detect anti-HCV antibod-
ies. The most widely used test is OraQuick-HCV, a rapid test
for anti-HCV antibody detection that consists on a finger stick.
Preferred samples are whole blood and plasma or serum, but
OraQuick-HCV can also detect antibodies in oral fluid although
with lower sensitivity, 97 ·6% versus 99 ·4%, with whole blood [34] .
This test can detect all HCV genotypes and gives the results in 20
min: a pink colour change that can be read at naked eye. It is a
reliable and easy-to-use test, perfect for diagnosis at point-of-care
[35] . However, OraQuick-HCV test price remains still high for its
implementation in large-scale screening. 
INNO-LIA HCV Score (INNOGENETICS, Ghent, Belgium), using a
line immunoassay (LIA), can detect anti-HCV antibodies on a nylon
strip, to get 6 different lines according to the recombinant antigen
detected in a sandwich reaction. It is possible to automatize this
method, reducing the laboratory personal needed, and with higher
sensitivity than OraQuick-HCV (100%) either in serum and in blood
samples [36] . 
Less known methods have been developed, such as SD Bioline
(Standard Diagnostics, South Korea), a rapid immunochromato-
graphic test approved by WHO [37] , developed to detect anti-HCV
antibodies from whole blood, serum, or plasma samples (100%
sensitivity and 99.4% specificity) (Standard Diagnostics). For HCV
screening, SD Bioline employs HCV recombinant antigens Core,
NS3, NS4, NS5, and this test has been developed for HAV, HBV,
and HIV as well [38] . In this line we find Assure HCV Multisure
rapid test (MP Biomedicals, Santa Ana, CA, USA) (99% sensitivity
and 99 ·8% specificity), and VIKIA® anti-HCV, (100% sensitivity and
99 ·7% specificity), but they have not been approved by WHO yet.
Tri-Dot (J. Mitra, India) is a rapid membrane based test similar
to ELISA for anti-HCV antibodies detection from serum or plasma
samples. With a 100% sensitivity and 98 ·9% specificity, Tri-Dot test
gives a visual result in 3 min [39] . As is shown, strip format is one of the preferred chosen for
OC systems, because it makes the test accessible for decen-
ralized settings . Sensitivity and specificity data show that if
MIC policies contributed to promote screening programs, rapid
OC tests would be great options for diagnosis in decentralized
ettings. Rapid POC tests do not need high qualified personal or
pecific instrumentation; they are usually easy to use, avoiding
ample transport to specialised settings. However, faster tests have
ot accomplished yet specificity and sensitivity of conventional
mmunoassays ( > 99 ·4% specificity and > 99 ·8% sensitivity) [4] . 
New molecular rapid POC tests using NAAT and core antigen
re the most desirable ones, and fast POC versions have been
eveloped. HCV Quant Assay [40] is a new HCV diagnostic test
or HCV RNA detection from plasma samples. It is an automated
ystem that uses paramagnetic particles for RNA extraction, and
hen performs a RT-qPCR to detect and quantify RNA. Using the
ew technology described by Kelso et al. (2017), all the process
an be done in a single device, with 100% sensitivity and 100%
pecificity. However, this system has not been developed yet to
e used by untrained personal, so it is difficult to implement HCV
uant Assay in low-resources settings. 
Xpert HCV Viral Load (Cepheid, Sunnyvale, CA) is another
utomated HCV RNA test. It consists on a cartridge where RNA
xtraction and conventional RT-PCR amplification are done from
 mL of serum or plasma samples; hence it does not require the
sually expensive NAAT equipment. This POC system has 100%
pecificity and it can quantify HCV viral load, comparable to the
idely used Abbott Real Time HCV assay [41] . Xpert HCV VL Fin-
erstick (Cepheid, Sunnyvale, CA) is another version of the assay
o quantify HCV RNA from drop blood samples [42] . This method
onsists on a fingerstick which detects and quantifies RNA in less
han an hour. Xpert HCV VL Fingerstick assay allows patients to
et their results in a single visit. Besides it needs less sample
reparation compared with Xpert HCV Viral Load [43] , but both
ests still suppose a high cost for low-resources settings. 
TaqMan Array Cards (TAC, Life Technologies, Grand Island, NY)
s a rapid test that has been developed for detection of HAV, HBV,
CV, HDV, and HEV RNA simultaneously (Kodani et al., 2014)
hich has 96% sensitivity and 98% specificity. It has recently been
pplied to multiplex detection of HIV-1 and HIV-2, additionally
o all hepatitis virus (Granade et al., 2018). Nevertheless, these
ultiplex assays has lowest sensitivity and specificity compared
o single RT-qPCR, but reduced costs, so they are not yet replacing
onventional methods but they are an important option to con-
ider when further studies were done. Improving sensitivity and
pecificity, these tests could be used in LMIC and for large-scale
creening where rapid tests are necessary [44 , 45] . 
A rapid new affordable POC diagnostic system based on detec-
ion of HCV core antigen is being developed by Daktari diagnostics
Boston, USA), a system that could perfectly fit in the requested
ethods for LMIC. Daktari system is based on microfluidic tech-
ology, and it would be able to analyse a blood drop in a single
artridge in 30 min [46] . This technology is also in development
or HIV. Again, as Xpert HCV VL Fingerstick [42] , this test would
llow patients to get their results in one visit, facilitating their
ccess to screening and diagnosis, maybe for both HIV and HCV at
he same time, allowing co-infection diagnosis. 
anotechnology in theragnosis 
Nanotechnology is becoming a larger important field in ther-
gnosis, specially referring to POC systems, since they require
ess sample volume and laboratory equipment, are more sensitive,
ime-affordable, and cost-effective. Most of them are paper-based
ystems which makes them easier to transport and storage [47–51] .
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Hepatitis C virus (Hwang, K. S. et al., 2007)
Mechanics
Microcantilever
Fig. 1. Scheme of a functionalized microcantilever for detection of HCV Helicase. Binding of HCV Helicase to the aptamers generates oscillations on the microcantilever. 
Nanomatherials




1) Lan, G. et al., 2011 2) Ma, K. et al., 2011
Electrochemical
signal changes
2) Hepatitis C virus (E2 protein) (Park, J. H. et al., 2013)1) Hepatitis C virus (Core protein) (Ghanbari, K. et al., 2017)
3) Hepatitis B virus (Xi, Z. et al., 2015)
Influenza A virus (Yeh, H. et al., 2010) Song, Y. et al., 2014
Ag-NC
Fig. 2. Schematic representation of diagnostic systems using nanomatherials. Ag-NC: silver nanocluster; SNP: single nucleotide polymorphism; Core Ag: Core antigen; HBsAg: 



















































e  Nanoparticles are usually the preferred chosen system, but also
echanics are making a place in diagnostics within the nanoscale
eld. For instance, the oscillations generated when a target binds
 microcantilever generate a signal that can be measured, allowing
he identification of the pathogen of interest [52 , 53] . Hwang et
l. (2007) developed a microcantilever diagnostic system for HCV,
mploying HCV Helicase as target [54] . 
Concerning the therapy, nanoparticles are an useful drug de-
ivery tool: nanoparticles can be functionalized with the drug or
hey can be functionalized with linkers that can recognise the
arget such as different DNA molecules [55] . Once the drug is
ncapsulated in the nanoparticle, drug stability, solubility, and
bsorption are enhanced [56] . The drug could be released thanks
o combination of diffusion and desorption mechanisms [57] . 
Nanotechnology also includes the use of dendrimers [58] ,
iposomes [59] , or carbon nanotubes [60] . Liposomes have been
uccessfully used for delivering AZT, a drug against HIV: its
iodisponibility in the target tissues was higher than administered
n the soluble conventional version [61] . 
Nanoparticles have been studied for treatment of infectious
iseases such as those caused by Escherichia coli and Staphylococcus
pidermidis . These systems are sequence-specific, since they use
NA-functionalized silver nanoclusters targeting specific regions
n the bacteria genome and thus inhibiting its growth [62] . 
DNA-functionalized nanoparticles or nanoclusters have been
mployed for diagnosis. Using silver nanoclusters, detections fluorescence emission of nanoclusters is enhanced when a  NA-functionalized nanoclusters bind to the target. Different
ystems have been developed based in this technology, as the
anoCluster Beacon designed by Yeh et al. (2010) for detection
f influeza A virus [63] and other similar systems for detection
f single nucleotide polymorphism or SNPs [64] , as this p53
ene mutation related with cancer [65] . Song et al. (2014), have
unctionalized streptavidin-coated paramagnetic beads and studied 
heir ability to detect PCR fragments immobilized in filter paper by
apillarity: paramagnetic beads can hybridize with PCR fragments
nd detection at naked eye takes just 2 min [51] . This kind of
ystems for DNA detection would be suitable for detection in early
tages of HCV infection; because of their reduced incubating time
his technology can facilitate the access of patients to diagnosis in
MIC since they could get their results in a single visit. 
NA aptamers: applications for HCV diagnosis 
RNA aptamers are single-stranded RNA oligonucleotides that
pecifically bind to a target molecule, which allow their employ-
ent for detection and even identification of different pathogen
nd tumour markers. Thus, aptamers are emerging as a key tool
or analytical diagnosis, that can be implemented in small POC
evices [37] . RNA aptamers have been used in the development of
CV serological tests. Enzyme Linked Aptosorbent Assay (ELASA),
s a new generation of aptamer-based assay developed by Park
t al. (2013) for detecting HCV E2 protein. In fact, two different
ptamers recognize two regions of E2 protein, through the capture
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Functionalized gold nanoparticles
A. DNA probes
Mycobacterium tuberculosis (Liandris, E. et al., 2009) Dengue virus (Carter, J. R. et al., 2013)
Influenza A virus (Liu, Y. et al., 2015)
Hepatitis C virus (Core protein) (Liu, Y. et al., 2013)
B. Antibodies
Influenza A virus (Zagorovsky, K. & Chan, W. C., 2013)
Fluorescence
emmision
Cancer cells (Bhattacharyya, K. et al., 2013)
Magnetic
detection
Staphylococcus aureus (Ju, Y. et al., 2013)




Fig. 3. Schematic representation of diagnostic systems using functionalized gold nanoparticles. Two different functionalization methods are represented, based on (A) DNA probes, 































































m  of the aptamer and a biotin-labelled detection, with a 3 ·13 × 10 2 
FPU/mL as detection limit [66] . 
Moreover, aptamers are used in new diagnostic methods for
detection of HCV antigens . Lee et al. (2007) developed a new
diagnostic tool based on the use of RNA aptamers, to detect
HCV core antigen in serum samples. The system consists on a
sol-gel based protein-chip where aptamers are immobilized. Once
they bind the core antigen Cy3-labelled human antibodies are
added for detection. Optimization of the system sensitivity is still
needed before starting using it for screening [67] . Chen et al.
(2009) developed a similar method to detect HCV E2 protein with
biotinylated ssDNA aptamers [68] . As well, Ghanbari et al. (2017)
have developed a electrochemical biosensor to detect HCV core
antigen [69] . Aptamers that target the Hepatitis B surface antigen
has been used in HBV diagnosis, a method that significantly
improved the sensitivity of conventional methods [70] . 
Gold nanoparticle-based biosensors for the diagnosis of 
infectious diseases 
Among the different types of nanoparticles, gold nanoparticles
are an emerging tool in POC diagnosis, and different tests are in
development. Gold nanoparticles-based assays have already been
employed for detection of infectious diseases and other harmful
biological agents, increasing and improving existing test’s options.
Gold nanoparticles have not been yet applied to HCV diagnosis
but they have been used for diagnosis of different infectious
diseases, such as Mycobacterium tuberculosis [71 , 72] , Helicobacter
pilori [73] , Dengue virus [74] , or influenza A virus [75] . Usually,
gold nanoparticles are functionalized with monoclonal antibodies
or DNA probes. Regarding DNA-modified gold nanoparticles, sDNA
probes like for H. pilori [73] are used or even include enzymatic
systems as DNAzyme (DNA oligonucleotides with catalytic activity
in presence of a specific target) like for Dengue virus [74] , or the
system described by Zagorovsky and Chan (2013) [76] potentiallypplicable for multiple targets. DNAzyme system is also used
n either biosensors for metal detection, to detect environmen-
al contamination or in toxicology assays [77] . With respect to
ntibody-modified gold nanoparticles, they have been used for
etection of influenza A virus [75] , or even circulating tumour
ells [78] . Sung et al. (2013) described a colorimetric biosensor
ased in the combination of antibody-modified gold and magnetic
anoparticles to enhance the detection signal for Staphylococcus
ureus and to reduce the assay time compared to ELISA [79] . 
As already mentioned before, nanoparticles can be functional-
zed with aptamers as small biosensors and using them especially
t POC. The usefulness of gold nanoparticles functionalized with
ptamers has allowed the development of nucleic acid lateral
ow strips for detection of HCV core antigen. These nanoprobes
pecifically bind to the HCV core protein and detection can be
etermined at naked eye [80] . 
However, it has been described that gold nanoparticles func-
ionalization is not always necessary since the presence of free
ucleic acids can change gold nanoparticles aggregation state and
odify their wavelength absorption. Specific probes can hybridize
ith target DNA. This change from free ssDNA to dsDNA alters
old nanoparticles stability and generates a wavelength change in
he visible spectrum, observable at naked eye. This principle has
een employed for detection of HBV [81] and also bacteria such
s Chlamydia trachomatis [82] , Lysteria monocytogenes [83] , and
almonella spp. Of note, this system shows both a high sensitivity
89 ·15%) and specificity (99 ·04%) for detection of Salmonella spp
84] . In all of these examples mentioned for un-modified gold
anoparticles, DNA amplification is necessary as a first step before
etection, and gold nanoparticles are employed instead of gel
lectrophoresis techniques. Indeed, Shawky et al. (2010) have
eveloped a method that detects non-amplified HCV RNA with
on-functionalized gold nanoparticles [85 , 86] . 
Nevertheless, nucleic acid extraction is a limiting step in
olecular diagnostics. Thus, if this step could be obviated it would
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Non-functionalized gold nanoparticles
DNA probes
Mycobacterium tuberculosis (Hussain, M. M. et al., 2013)
Hepatitis B virus (Liu, M. et al., 2011)
Chlamydia trachomatis (Jung, Y. L. et al., 2010), Listeria monocytogenes (Fu, Z. et al., 2013) y 
Salmonella enterica (Prasad, D. et al., 2011)
Hepatitis C virus (Shawky, S. M. et al., 2010)
Fig. 4. Schematic representation of diagnostic systems using non-functionalized gold nanoparticles. AuNPs: gold nanoparticles; SNP: single nucleotide polymorphism; Core Ag: 
Core antigen. 
Table 1 
Summary of diagnostic methods for bacterial/viral pathogens, and cancer cells using nanotechnology systems. 
Organism Detection Reference 
Mechanics 
HCV (Helicase) Microcantilever Hwang et al. (2007) [54] 
Nanomatherials 
Influenza A virus Nanocluster Beacon Yeh. et al. (2010) [63] 
Cancer cells Single nucleotide polymorphism Lan et al. (2011) [64] , Ma et al. (2011) [65] 
- Paramagnetic beads Song et al. (2014) [51] 
HCV (E2 protein) Aptamers Chen et al. (2009) [68] , Park et al. (2013) [66] 
HCV (Core protein) Aptamers Lee et al. (2007) [67] , Ghanbari et al. (2017) [69] 
HBV Aptamers Xi et al. (2015) 
Functionalized gold nanoparticles 
Mycobacterium tuberculosis DNA probes Liandris et al. (2009) [72] 
Helicobacter pilori DNA probes Gill et al. (2008) [73] 
Dengue virus DNA probes Carter R. et al. (2013) [74] 
Influenza A virus DNA probes Zagorovsky & Chan (2013) [76] 
HCV (Core protein) Aptamers Liu et al. (2013) [80] 
Influenza A virus Antibodies Liu et al. (2015) [75] 
Cancer cells Antibodies Bhattacharyya (2013) [78] 
Staphylococcus aureus Antibodies Ju et al. (2013) [79] 
Non-functionalized Gold nanoparticles 
Mycobacterium tuberculosis DNA probes Hussain et al. (2013) [71] 
HBV DNA probes Liu et al. (2011) [81] 
Chlamydia trachomatis DNA probes Jung et al. (2010) [82] 
Listeria monocytogenes DNA probes Fu et al. (2013) [83] 
Salmonella enterica DNA probes Prasad et al. (2011) [84] 








































s  emarkably reduce the assay time. In summary, the principal
haracteristic of gold nanoparticle-based tests is that they are
olorimetric, so no final detection reaction is needed to get the
esult but visualizing at naked eye. Besides they seem to be sen-
itive enough in preliminary studies. Therefore gold nanoparticle
ests are cost-effective and time-saving as well as suitable for LMIC
here no specialized personal or laboratory equipment is available.
onclusion 
HCV is still an under-diagnosed infection, especially in low-
esource settings, so new diagnostic tests are urgently required.
owadays, a plethora of new methods are in development, which
ould greatly overcome drawbacks of current HCV tests. New
eneration of HCV test should be cost-effective, time-saving, and
asy to implement in low-resource settings where no highly spe-
ialized personal is available. Nanotechnology-based tests espe-
ially meet POC requirements, so it is a highly important emerg-
ng field to take into account when looking for solutions in
MIC. Besides, ongoing POC tests usually target nucleic acids, an
ssential requirement for HCV diagnosis in early stages, reduc-
ng percentage of under-diagnosed population. Thus, the use of
anotechnology-based tests for the diagnosis of HCV infection mayvercome the diagnostic access and the undiagnosed of HCV infec-
ion, leading up to the WHO objective towards the HCV elimina-
ion. 
earch strategy and selection criteria 
In this review, we searched PubMed, Medline, Web of Science
nd Google Patents databases. Search terms included “Hepatitis
 virus”, “HCV”, “HCV coinfection”, “diagnosis”, “diagnostic tests”,
nanotechnology diagnostic methods”, “point-of-care”, and “rapid
iagnostic tests” to identify articles published before November, 
018. Reference lists of selected papers where manually searched
or additional papers covering topic of interest. We also searched
n online websites such as World Health Organisation (WHO)
ebsite for HCV guidelines. Articles, patents, and guidelines in
nglish and Spanish were included. 
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